Innoviva Price to Book Ratio 2010-2024 | INVA

Historical price to book ratio values for Innoviva (INVA) over the last 10 years. The current price to book ratio for Innoviva as of April 25, 2025 is 1.66.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Innoviva Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2025-04-25 18.24 1.65
2024-12-31 17.35 $11.03 1.57
2024-09-30 19.31 $10.68 1.81
2024-06-30 16.40 $10.64 1.54
2024-03-31 15.24 $11.21 1.36
2023-12-31 16.04 $10.66 1.50
2023-09-30 12.99 $9.75 1.33
2023-06-30 12.73 $8.51 1.50
2023-03-31 11.25 $8.53 1.32
2022-12-31 13.25 $8.18 1.62
2022-09-30 11.61 $9.19 1.26
2022-06-30 14.76 $8.11 1.82
2022-03-31 19.35 $7.93 2.44
2021-12-31 17.25 $7.56 2.28
2021-09-30 16.71 $7.08 2.36
2021-06-30 13.41 $5.67 2.37
2021-03-31 11.95 $6.87 1.74
2020-12-31 12.39 $5.99 2.07
2020-09-30 10.45 $5.28 1.98
2020-06-30 13.98 $4.86 2.88
2020-03-31 11.76 $4.01 2.94
2019-12-31 14.16 $3.38 4.19
2019-09-30 10.54 $2.80 3.76
2019-06-30 14.56 $2.44 5.98
2019-03-31 14.03 $1.98 7.10
2018-12-31 17.45 $1.57 11.09
2018-09-30 15.24 $-1.07 -14.22
2018-06-30 13.80 $-1.53 -9.03
2018-03-31 16.67 $-2.10 -7.94
2017-12-31 14.19 $-2.38 -5.96
2017-09-30 14.12 $-2.06 -6.84
2017-06-30 12.80 $-2.71 -4.72
2017-03-31 13.83 $-3.06 -4.52
2016-12-31 10.70 $-3.26 -3.29
2016-09-30 10.99 $-3.36 -3.27
2016-06-30 10.53 $-3.26 -3.23
2016-03-31 12.59 $-3.20 -3.93
2015-12-31 10.54 $-2.99 -3.53
2015-09-30 7.18 $-2.75 -2.61
2015-06-30 17.74 $-2.51 -7.06
2015-03-31 15.21 $-2.23 -6.83
2014-12-31 13.52 $-1.92 -7.04
2014-09-30 16.04 $-1.68 -9.57
2014-06-30 27.65 $-1.66 -16.70
2014-03-31 23.15 $2.34 9.89
2013-12-31 26.67 $2.68 9.94
2013-09-30 30.57 $2.99 10.24
2013-06-30 28.82 $0.85 33.91
2013-03-31 17.67 $0.92 19.17
2012-12-31 16.64 $1.58 10.56
2012-09-30 19.38 $1.77 10.94
2012-06-30 16.62 $1.95 8.51
2012-03-31 14.59 $0.07 205.74
2011-12-31 16.53 $-1.02 -16.25
2011-09-30 15.07 $-0.69 -21.68
2011-06-30 16.61 $-0.44 -37.57
2011-03-31 18.12 $-0.33 -54.52
2010-12-31 18.75 $-0.28 -67.22
2010-09-30 15.04 $-1.91 -7.88
2010-06-30 9.40 $-1.71 -5.50
2010-03-31 9.96 $-1.55 -6.44
2009-12-31 9.78 $-2.94 -3.32
2009-09-30 10.95 $-2.76 -3.97
2009-06-30 10.95 $-2.52 -4.34
2009-03-31 12.72 $-2.30 -5.53
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.145B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $796.425B 64.61
Johnson & Johnson (JNJ) United States $379.479B 15.67
AbbVie (ABBV) United States $306.016B 17.09
Novo Nordisk (NVO) Denmark $260.636B 17.65
Roche Holding AG (RHHBY) Switzerland $248.102B 0.00
Novartis AG (NVS) Switzerland $234.183B 14.19
Merck (MRK) United States $196.697B 10.21
Sanofi (SNY) France $128.587B 12.24
Pfizer (PFE) United States $125.566B 7.12
Bayer (BAYRY) Germany $23.657B 4.39